Comparative Pharmacology
Head-to-head clinical analysis: VIDEX versus VIDEX EC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: VIDEX versus VIDEX EC.
VIDEX vs VIDEX EC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Didanosine, a synthetic purine nucleoside analogue of deoxyadenosine, is phosphorylated to active metabolite dideoxyadenosine triphosphate (ddATP), which inhibits HIV-1 reverse transcriptase by competing with natural substrate dATP and causing chain termination after incorporation into viral DNA.
Nucleoside reverse transcriptase inhibitor (NRTI); intracellularly phosphorylated to active metabolite didanosine triphosphate, which inhibits HIV reverse transcriptase by competing with natural deoxynucleotides and causing DNA chain termination.
Adults: 200 mg orally twice daily (two 100 mg chewable tablets per dose) or 250 mg orally twice daily (two 125 mg buffered powder packets per dose); administer on an empty stomach (at least 30 minutes before or 2 hours after a meal).
400 mg orally once daily on an empty stomach.
None Documented
None Documented
Terminal elimination half-life: 1.5-2 hours (intravenous), prolonged to 4-8 hours in renal impairment. Clinical context: Requires dose adjustment in CrCl <50 mL/min.
0.6–1.5 hours (short terminal half-life due to rapid intracellular phosphorylation and cellular retention of active triphosphate; clinical dosing accounts for intracellular half-life of ~12–15 hours)
Renal elimination: approximately 50-60% of dose excreted unchanged in urine via glomerular filtration and active tubular secretion. Fecal elimination: <20% as unchanged drug or metabolites.
Renal: >50% unchanged via glomerular filtration and tubular secretion; minimal biliary/fecal excretion (<2%)
Category C
Category C
Nucleoside Reverse Transcriptase Inhibitor
Nucleoside Reverse Transcriptase Inhibitor